BURDEN OF DISEASE AND MANAGEMENT OF MESOTHELIOMA IN FRANCE- A NATIONAL COHORT ANALYSIS
Author(s)
Tournier C1, Blein C2, Monnet I3, Andujar P3, Vainchtock A2, Scherpereel A4, Pairon JC3, Chouaid C5
1HEVA, LYON, France, 2HEVA, Lyon, France, 3CHI CRETEIL, CRETEIL, France, 4CHU Lille, Lille, France, 5Centre Hospitalier Intercommunal, DHU-ATVB, Département de Pneumologie et Pathologie Professionnelle, Créteil, France
OBJECTIVES: Malignant pleural mesothelioma (MPM) is an uncommon cancer with poor survival. The aim of the study is to determine the burden of MPM disease and analyze associations between socioeconomic deprivation and urbanization survival in France. METHODS: Hospital stays with ICD-10 codes C45.0 and C45.9 as principal/related or significantly associated diagnosis (DP/DR/DAS) were extracted from the PMSI-MCO 2011/2012 database MPM incident patients were selected (absence of MPM codes and C34*/C38.4 codes as DP/DR/DAS since 2006 and a medical review was conducted) and were followed for 2 years from their first stay. Cox models were used to express survival at 1 and 2 years in France regarding different indicators as a population density index (PDI) and a social deprivation index (SDI) based on census data aggregated at the municipalities level. RESULTS: The cohort comprised 1,890 incident patients of MPM (men: 76%; age at inclusion: 73.6±10.0 years; presence of comorbidities during the follow-up: 84%). Patients mainly lived in urban zones (57%) and had a low IDS (53%). Only 1% of patients had a surgical specific procedure; 65% at least one chemotherapy administration (42% and 20% on the three and the last month of life, respectively); 5% at least an admission on intensive care unit (6% and 5% on the three and the last month of life, respectively). Survival rate at 1-year and 2-year was 64% and 48%, respectively. In adjusting analysis on age, gender and comorbidities (hypertension, diabetes, renal insufficiency, COPD, pulmonary insufficiency, and other chronic lung diseases), PDI was significantly associated with death at 1-year (HR=0.82 [0.72-0.96]) and 2-years (HR=0.83 [0.73-0.94]) and SDI being non-significant variable in the univariate analysis. CONCLUSIONS: MPM remains a disease with a poor prognostic of survival (64% and 48% at 1 and 2-years, respectively) and significantly associated with comorbidities and PDI.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PHS100
Topic
Health Service Delivery & Process of Care, Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems, Treatment Patterns and Guidelines
Disease
Oncology